|
- Dyne Therapeutics - A biotechnology company developing nucleic acid . . .
Culture and careers Our commitment to people living with neuromuscular diseases is our greatest strength Hear our Dynamos share their perspective on what makes Dyne a special place to work Learn more
- Dyne - Wikipedia
The dyne (symbol: dyn; from Ancient Greek δύναμις (dúnamis) 'power, force') is a derived unit of force specified in the centimetre–gram–second (CGS) system of units, a predecessor of the modern SI
- Dyne plans to submit next-gen Duchenne drug to FDA - STAT
Dyne Therapeutics plans to submit its next-gen Duchenne muscular dystrophy drug to the FDA after a successful trial
- Dyne readies FDA push after DMD exon 51 med excels in trial
Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy, challenger from Massachusetts biotech Dyne
- Dyne Therapeutics Announces Positive Topline Results from . . . - BioSpace
Dyne also continues to pursue approval pathways outside of the U S for z-rostudirsen in patients with DMD who are amenable to exon 51 skipping Investor Webcast Dyne will host a conference call and webcast to discuss these updates today, December 8, 2025, at 8:00 a m ET and a replay will be accessible for 90 days following the presentation
- Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares . . .
Dyne is readying a competitor to Sarepta’s Exondys 51 Elsewhere, a pair of obesity drugs showed promise and Kymera’s protein-degrading medicine displayed “biologic-like or better efficacy,” according to one analyst
- Dyne says Duchenne drug succeeds in pivotal study, heads to FDA for . . .
Dyne Therapeutics announced Monday that its Duchenne muscular dystrophy drug z-rostudirsen hit the primary endpoint in a key study and plans to take the experimental treatment to the FDA for accelerated approval
- Dyne Therapeutics (DYN) FDA Approvals - MarketBeat
Over the past two years, Dyne Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as DYNE-101, DYNE-251, and DYNE-302
|
|
|